Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck - Test2 - elhamkhani - TriplyDB

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

http://www.wikidata.org/entity/Q29619277

about

HPV & head and neck cancer: a descriptive update Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy Interventions for the treatment of oral and oropharyngeal cancers: immunotherapy/biotherapy Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas Patient-derived tumour xenografts as models for oncology drug development The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-α-1,3-galactose From combinatorial peptide selection to drug prototype (II): targeting the epidermal growth factor receptor pathway Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents The promise of immunotherapy in head and neck squamous cell carcinoma The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors HPV Positive Head and Neck Cancers: Molecular Pathogenesis and Evolving Treatment Strategies Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC)Advanced oropharyngeal squamous cell carcinoma: Pathogenesis, treatment, and novel therapeutic approaches Molecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinoma Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential Oral Mucositis Induced By Anticancer Therapies The Tip of the Iceberg: Clinical Implications of Genomic Sequencing Projects in Head and Neck Cancer Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications Cutaneous adverse reactions specific to epidermal growth factor receptor inhibitors Recent Progress in Therapeutic Treatments and Screening Strategies for the Prevention and Treatment of HPV-Associated Head and Neck Cancer Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses Human Papillomavirus (HPV)-associated Oral Cancers and Treatment Strategies Targeted Therapy in Oropharyngeal Squamous Cell Carcinoma: The Implications of HPV for Therapy Role of CT perfusion in monitoring and prediction of response to therapy of head and neck squamous cell carcinoma Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck Improving the efficacy of chemoradiation with targeted agents Clinical applications of palifermin: amelioration of oral mucositis and other potential indications Combining targeted agents and hypo- and hyper-fractionated radiotherapy in NSCLC Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer HPV in oropharyngeal cancer: the basics to know in clinical practice The role of systemic treatment before, during, and after definitive treatment Radiotherapy and "new" drugs-new side effects?Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity

P2860

Q21198763-82775337-329D-4BBD-AFC3-C7363DA77F7B Q21198850-FF1F92D6-A337-458C-A1E4-B1B082791156 Q24187274-693F86F4-34FD-4DF9-8693-8BDC9E15E586 Q24202546-252052F3-43AB-4CFC-B5CE-AB920E4B3A68 Q24235245-A0118546-C67F-437B-9E0D-79F5A8FA35EF Q24336818-2989D432-91DE-4F23-A54B-B4F5486307FC Q24604068-3B54D5E3-C74A-4325-A675-C4F50922ABB9 Q24604244-BC256F7E-C9BC-49BA-8BB7-EB0EB789C1B9 Q24621007-EA21F8F7-FBA8-4C67-9729-3F855B01143E Q24645217-0EEAB21A-8D8A-4270-96C4-5A169B45439A Q24652337-81F8E6F9-C8A9-4129-A149-AD9DC3C315F0 Q26740567-4DC00629-00E4-4EED-A797-07CCAFBB756F Q26744433-06DD8894-BFDC-4955-9587-8317249EE725 Q26747516-27B1F8DD-058F-45A8-B3AD-E469828B26B7 Q26750719-3CB8211B-7236-4EE2-9507-1EEED1AF6DFC Q26752584-4B586645-724F-4AB0-B4DB-FEE355DDE009 Q26765060-C3CA5D33-8C40-47AD-88EE-1B5B38912FFB Q26765429-4237DA8A-B977-4ADB-A710-DBB7D3A8AC8C Q26767046-3C4A0387-4866-48A4-ACCF-D3CDEA271B4B Q26767182-69AAA701-FA79-49D6-B99E-4D88C12CE22E Q26769884-3086699D-F9B8-44F6-B926-DEA22A0E6F68 Q26777493-5EEB5B73-8688-40B8-95FF-ECFD08EE1A5F Q26778433-D234C656-3B4F-4C55-86C8-BE19516ADCB8 Q26779221-A3001240-DC02-45B1-AA83-5948D47B5132 Q26781472-6172BFD7-20DC-4907-96F0-37D1C01A4234 Q26782255-69101F6B-2369-430F-BB33-C21425ED12D0 Q26786243-B211FFB7-6BEA-4DAD-B178-F9B953E77701 Q26822621-2B54B6E0-1E98-4F76-B388-8117B4950D67 Q26824925-7953AA23-C21D-4539-878E-1554DDDC0C80 Q26825536-1D4C11BA-CCCE-46CE-A343-A78F6FC86570 Q26827571-FE45A7AE-1F82-42C0-AB68-72667B22E270 Q26830495-D253EA09-14CD-4792-9CC7-F9196175A6FF Q26850193-48FE4BC7-1015-4110-92DE-F976E44F2469 Q26852139-C53D09CC-FCE1-4A23-890D-7D9D92B8931F Q26852202-5FD104E5-038D-4229-B86D-C40D54058BA3 Q26852215-8378A264-5951-4D93-8C96-14AFD0945ED5 Q26853669-60B54007-0F4A-4349-9AFA-D213168FC422 Q26859285-31CA68F4-0840-48B5-B1A8-ABDB57D3A61C Q26861498-9B8BB458-CE62-4D22-A046-BA8952DC5804 Q26862220-8EAF6A01-96FC-4B2C-86CE-6EDEEEBD9F16

P2860

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

http://www.wikidata.org/entity/Q29619277

description

2006 nî lūn-bûn

@nan

2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

@ast

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

@en

type

label

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

@ast

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

@en

prefLabel

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

@ast

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

@en

P1433

Q29619277-CD5728BF-0CF6-4BB2-AE15-B3EA98DD00E9

P1476

Q29619277-44B8EAE0-953B-43C6-9CC6-C77D4EB2FCF8

P2093

Q29619277-1E81DDCF-2E16-415C-9885-52504756694A

Q29619277-22F5D27A-67A8-41F4-B13C-E645EDF4611A

Q29619277-3CF261B0-78B0-4DCA-B704-8847FF21BE1E

Q29619277-48B29616-C1C4-4682-AB8F-B18F3F6DF49E

Q29619277-53469483-A85D-4C17-973D-32BC70076CC4

Q29619277-551D2FE3-C7A6-4E6B-BF59-CCB4C070ABBF

Q29619277-5652083B-8A85-4360-B6D3-32028FE642ED

Q29619277-72BF8C5F-E874-41CD-987A-431D8793F496

Q29619277-758C2DE3-AED7-4479-9B72-20AF39B771DF

Q29619277-AE239F05-1E3F-4216-8831-9EAC25FBD308

P304

Q29619277-5A6D6E2B-A6D5-4D2D-8409-7B40A76BE187

P31

Q29619277-97835BB7-2E26-4CD0-B61A-97665B2B731D

P3181

Q29619277-98464D37-2CFA-4FE7-B839-7AB0B1BD130C

P356

Q29619277-6B01F188-A193-4398-8627-3124B9A6F4A0

P407

Q29619277-430F621E-EE7D-43A5-B6AA-93A14E3705C7

P433

Q29619277-DA985792-C35E-4BEC-AF8E-E22661A7A230

P478

Q29619277-038748FA-22B8-4328-BA84-4A722AC3FDAA

P50

Q29619277-F7442D5D-3680-4626-90D6-EBEFA316F664

P577

Q29619277-47C447DF-A07A-47BC-BD5E-F18043E962E3

P698

Q29619277-719B0B41-DC87-4AFB-AFE9-4FCB2F271A18

P921

Q29619277-4529FED5-8212-474F-B7FB-AC767471A19A

Q29619277-AB44FF6A-B198-48BF-8EE4-EAAC0A4997BE

P3181

P356

P1433

The New England Journal of Medicine

P1476

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

@en

P2093

Amellal N

http://www.w3.org/2001/XMLSchema#string

Ang KK

http://www.w3.org/2001/XMLSchema#string

Azarnia N

http://www.w3.org/2001/XMLSchema#string

Baselga J

http://www.w3.org/2001/XMLSchema#string

Bonner JA

http://www.w3.org/2001/XMLSchema#string

Cohen RB

http://www.w3.org/2001/XMLSchema#string

Harari PM

http://www.w3.org/2001/XMLSchema#string

Jassem J

http://www.w3.org/2001/XMLSchema#string

Jones CU

http://www.w3.org/2001/XMLSchema#string

Kies MS

http://www.w3.org/2001/XMLSchema#string

P304

567-78

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

512982

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA053422

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

354

http://www.w3.org/2001/XMLSchema#string

P50

Jordi Giralt López de Sagredo

P577

2006-02-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16467544

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy